View in browser In vitro methods have seen a significant uptake according to ECHA ECHA's latest report highlights the recent progress for the use of alternatives to animal testing for chemical safety assessment. We are proud to be part of this movement and are committed to promoting the long-term use of alternative methods, contributing to a more human relevant and sustainable approach to safety assessment. Read the ECHA report here Is it time to develop an evidence-based approach for the biological safety assessment of medical devices? asks Ron Brown We were delighted to have Ron Brown, a renowned toxicologist and former FDA risk assessor, join us for one of our webinars. During the session, Ron discussed the need for a new and agile approach to the biological safety assessment of medical devices. Thank you, Ron, for a great presentation on such an important topic! View the recording to gain valuable insights and explore SenzaGen's in vitro biocompatibility testing package  Expanded GARD availability We are expanding our distributor network to meet the increasing demand for in vitro toxicology and our innovative GARD® test portfolio. Collaborations with specialist CROs help us provide better access to our services. We are excited to welcome GV Research Platform (GVRP) in India and Oroxcell in France as our latest partners.  Upcoming events 🌎 Conference: WC12 | Niagara Falls, Canada | August 27-31, 2023  🌎 Conference: Eurotox | Ljubljana, Slovenia | Sep 10-13 Copyright © SenzaGen 2023 All rights reserved. SenzaGen AB | Medicon Village | 223 81 Lund, Sweden You are receiving this email because you expressed interest in SenzaGen's technology in the past. Unsubscribe here if you do not wish to receive technology updates and news from us.